Cost-effectiveness of prophylaxis with recombinant versus plasma-derived VWF in severe von Willebrand disease in the US.
Christina J WaldronSatoko ItoDaniel WangCecily AllenGiri ViswanathanRobert D BonaAdam CukerGeorge GoshuaPublished in: Blood (2024)
We evaluated the cost-effectiveness of prophylaxis with rVWF versus with pdVWF for patients with severe VWD. We found that rVWF is a cost-saving factor replacement compared to pdVWF across all willingness-to-pay thresholds in the United States.
Keyphrases